Table 1.

Patient characteristics.

	Crohn’s disease		Ulcerative colitis
Age	49 (n = 30)		46.2 (n = 21)
Sex	Female	n = 16 (53.3%)	Female	n = 13 (61.9%)
	Male	n = 14 (46.7%)	Male	n = 8 (38%)
Race	White	n = 27 (90%)	White	n = 17 (80.9 %)
	Black	n = 2 (6.7%)	Black	n = 1 (4.8%)
	Other	n = 1 (3.3%)	Native American	n = 1 (4.8%)
			Other	n = 2 (9.5%)
Smoking status	Current	n = 1 (3.3%)	Current	n = 0 (0%)
	Never	n = 23 (76.7%)	Never	n = 18 (85.7%)
	Past	n = 6 (20%)	Past	n = 3 (14.3%)
Location (Montreal classification)	L1	n = 3 (10%)	E1	n = 6 (28.6%)
	L2	n = 4 (13.3%)	E2	n = 7 (33.3%)
	L3	n = 21 (70%)	E3	n = 8 (38%)
	L4	n = 2 (6.7%)
Behaviour (Montreal classification)	B1	n = 11 (36.7%)
	B2	n = 10 (33.3%)
	B3	n = 4 (13.3%)
	P	n = 5 (16.7%)
Disease activity at baseline	CDAI		Partial Mayo score
	<150 (remission)	n = 13 (43.3%)	≤2 (remission)	n = 2 (9.5%)
	150–220 (mild)	n = 8 (26.7%)	3–4 (mild)	n = 6 (28.6%)
	220–450 (moderate)	n = 7 (23.3%)	5–6 (moderate)	n = 6 (28.6%)
	>450 (severe)	n = 2 (6.7%)	7– 9 (severe)	n = 7 (33.3%)
	HBI
	<5 (remission)	n = 4 (13.3%)
	5–7 (mild disease)	n = 4 (13.3%)
	8–16 (moderate disease)	n = 18 (60%)
	>16 (severe disease)	n = 4 (13.3%)
Number of prior TNFα inhibitor used	0	n = 1 (3.3%)	0	n = 5 (23.8%)
	1	n = 7 (23.3%)	1	n = 8 (38%)
	2	n = 11 (36.7%)	2	n = 7 (33.3%)
	3	n = 11 (36.7%)	3	n = 1 (4.8%)
Number of prior immunomodulators used (excluding current users)	AZA and/or 6MP	n = 16 (53.3%)	AZA and/or 6MP	n = 6 (28.7%)
	MTX	n = 6 (20%)	MTX	n = 2 (9.5%)
Number of prior surgeries	0	n = 16 (53.3%)	0	n = 20 (95.2%)
	1	n = 8 (26.7%)	1	n = 1 (4.8%)a
	2	n = 5 (16.7%)
	3	n = 1 (3.3%)
Steroid use at baseline	Oral	n = 8 (26.7%)	Oral	n = 3 (14.3%)
	Topical	n = 12 (40%)	Topical	n = 7 (33.3%)
Immunomodulator use at baseline	Total	n = 21 (70%)	Total	n = 10 (47.6%)
	AZA and/or 6MP	n = 12 (40%)	AZA and/or 6MP	n = 10 (47.6%)
	MTX	n = 9 (30%)	MTX	n = 0 (0%)

AZA, azathioprine; 6MP, mercaptopurine; MTX, methotrexate.

^a Patient had right hemi-colectomy for adenocarcinoma prior to UC diagnosis.